In Washington, even widely hailed programs with bipartisan support — like the rare pediatric disease priority review voucher ...

SOUTH SAN FRANCISCO, CA, USA I April 01, 2025 I TheRas, Inc. d/b/a BridgeBio Oncology Therapeutics (“BBOT” or the “Company”), a clinical-stage ...

BridgeBio Pharma, Inc. (NASDAQ:BBIO – Get Free Report) was the recipient of unusually large options trading on Monday. Traders acquired 8,235 call options on the stock. This is an increase of 88% ...

Equities research analysts at Redburn Atlantic began coverage on shares of BridgeBio Pharma (NASDAQ:BBIO – Get Free Report) in a research note issued on Monday, Marketbeat.com reports. The firm set a ...

Fintel reports that on March 31, 2025, Redburn Atlantic initiated coverage of BridgeBio Pharma (NasdaqGS:BBIO) with a Buy ...

Pharma presented results showing statistically significant improvements in clinical outcomes as compared to placebo for time ...

Acoramidis’s hazard ratio of .41 for time to ACM or first CVH versus placebo in the ATTRibute-CM study subgroup of ATTRv-CM ...

BridgeBio Pharma’s Beyonttra to treat transthyretin-mediated amyloid cardiomyopathy receives Japanese approval: Palo Alto, California Monday, March 31, 2025, 17:00 Hrs [IST] Bri ...

We recently published a list of the 10 Best Mid Cap Biotech Stocks to Buy. In this article, we are going to take a look at ...

Based on the terms of the agreement, BridgeBio will receive a $30 million milestone payment upon approval in Japan, as well ...

BridgeBio Pharma (BBIO) announced the Japanese Ministry of Health, Labour and Welfare, MHLW, has approved acoramidis, under the brand name ...

With these trends in view, let’s look at the 10 best mid cap biotech stocks to buy.